Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
复制标题
与钆维塞胺暴露相关的肾源性系统性纤维化：硫代硫酸钠治疗。
DOI：
10.1053/j.ajkd.2008.09.016
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
M. Perazella
中科院分区：
文献类型：
--
作者：
Deepak Kadiyala;D. Roer;M. Perazella
肾源性系统性纤维化（NSF）是肾脏疾病患者的一种衰弱性纤维化疾病，与钆造影剂暴露有关。大多数病例与钆双胺有关。Gadoversetamide是一种与gadodiamide具有类似螯合特性的药物，很少被描述为引起NSF。除了使肾功能正常化外，对NSF患者没有一致有效的治疗方法。我们描述了3例终末期肾病患者在钆造影剂暴露后发生NSF的病例。2例患者接受加多弗赛特胺治疗，3例接受加多二胺治疗。所有3例患者均在病程早期接受静脉注射硫代硫酸钠治疗，皮肤变化和关节活动度均有所改善。
Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure. Most cases are linked to gadodiamide. Gadoversetamide, an agent with chelate characteristics similar to gadodiamide, has rarely been described to cause NSF. With the exception of normalization of kidney function, there are no consistently effective therapies for patients with NSF. We describe 3 cases of NSF in patients with end-stage renal disease after gadolinium-based contrast exposure. Two patients received gadoversetamide and the third received gadodiamide. All 3 patients were treated early in their disease course with intravenous sodium thiosulfate and responded with improved skin changes and joint mobility.